Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome.

ABSTRACT: Gastric cancer is the second leading cause of cancer-related deaths worldwide. Conventional cytotoxic chemotherapy has limited efficacy for metastatic gastric cancer, with an overall survival of approximately ten months. Recent advances in high-throughput technologies have enabled the implementation of personalized cancer therapy for high-risk patients. The use of such high-throughput technologies, including microarray and next generation sequencing, have promoted the discovery of novel targets that offer new treatment strategies for patients lacking other therapeutic options. Many molecular pathways are currently under investigation as therapeutic targets in gastric cancer, including those related to the epidermal growth factor receptor family, the mesenchymal-epithelial transition factor

SUBMITTER: Lim SM 

PROVIDER: S-EPMC3934474 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature